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Abstract
Background
Serum bactericidal antibody titres that correlate with protection against invasive meningo-
coccal disease have been characterised. However, titres that are associated with protection
against acquisition of pharyngeal carriage of Neisseria meningitidis are not known.
Methods
Sera were obtained from the members of a household in seven countries of the African men-
ingitis belt in which a pharyngeal carrier of N. meningitidis had been identified during a
cross-sectional survey. Serum bactericidal antibody titres at baseline were compared
between individuals in the household of the carrier who became a carrier of a meningococ-
cus of the same genogroup during six months of subsequent follow-up and household mem-
bers who did not become a carrier of a meningococcus of this genogroup during this period.
Results
Serum bacterial antibody titres were significantly higher in carriers of a serogroup W or Y
meningococcus at the time of recruitment than in those who were not a carrier of N. meningi-
tidis of the same genogroup. Serum bactericidal antibody titres to a strain of N. meningitis of
the same genogroup as the index cases were no different in individuals who acquired
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carriage with a meningococcus of the same genogroup as the index case than in those who
did not become a carrier during six months of follow-up.
Conclusion
Serum bacterial antibody titres to N. meningitidis of genogroup W or Y in the range of those
acquired by natural exposure to meningococci of these genogroups, or with cross-reactive
bacteria, are not associated with protection against acquisition of carriage with meningo-
cocci of either of these genogroups.
Introduction
Infection with Neisseria meningitidis (the meningococcus) usually results in an asymptomatic,
or only mildly symptomatic, infection of the pharynx; invasion of the blood stream and inva-
sive disease is a rare event. Study of pharyngeal carriage is, therefore, essential for a full under-
standing of the epidemiology of meningococcal infection [1]. The importance of carriage has
been emphasised by the demonstration that the success of meningococcal conjugate vaccines
in containing outbreaks of meningococcal disease in both industrialised countries [2,3] and in
the African meningitis belt [4,5] is very dependent upon their ability to prevent carriage.
Studies with polysaccharide and conjugate vaccines have shown a strong correlation
between vaccine induced serum bactericidal antibody (SBA) titre and protection against inva-
sive meningococcal disease [6–8], an association that has been considered sufficiently robust
to allow the licensure of meningococcal conjugate vaccines on the basis of immunogenicity
and safety, without the requirement for a phase 3 efficacy trial [9,10]. However, little is known
about the relationship between SBA and protection against pharyngeal carriage. A high SBA
titre is associated with current carriage [11,12], with an increase in titre observed shortly fol-
lowing colonisation [13,14] and persistence for many months after clearance. A mathematical
model confirmed that the relationship between the observed prevalence of group B meningo-
coccal SBA and carriage by age of group B meningococci in the United Kingdom is consistent
with a mechanism whereby episodes of carriage induce SBA activity [15]. In a study under-
taken in Burkina Faso, both residence in an epidemic district and current carriage of group W
N. meningitidis were independent predictors of high SBA titres, supporting the view that ele-
vated titres may persist after clearance [16]. Taken together, this evidence suggests that SBA
develop shortly after colonisation and remains elevated until clearance, after which SBA wane.
However, whether SBA can prevent the acquisition of carriage of N. meningitidis and, if this is
the case, how high a titre of antibody is required to achieve protection, is not known. Studies
of pneumococcal and Haemophilus influenzae type b (Hib) infection suggest that the antibody
titre required to prevent acquisition of carriage is higher than that needed to prevent invasive
disease [17–20] but whether this is also the case for meningococcal disease has not been
determined.
Members of the MenAfriCar Consortium have recently undertaken a series of studies of
pharyngeal carriage of N. meningitidis in the African meningitis belt [21–23], including a study
of patterns of transmission of the meningococcus within the household of a carrier identified
during an initial cross-sectional survey [22]. A blood sample was obtained from each house-
hold member on entry into this study, allowing the relationship between the titre of bacteri-
cidal antibody present at the time of enrolment to the risk of becoming a carrier within the
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subsequent six months of follow-up to be investigated. The results of this investigation are
described in this paper.
Methods
Field studies
Twenty cross-sectional surveys of meningococcal carriage were undertaken in seven countries
across the African meningitis belt (Chad, Ethiopia, Ghana, Mali, Niger, Nigeria and Senegal)
in 2010, 2011 and 2012 [22]. Households were selected randomly from an existing Demo-
graphic Surveillance System or from a census that was performed specifically for the study.
Following provision of informed consent, up to five individuals per household, stratified by
age (less than 1 year, 1–4 years, 5–14 years, 15–29 years and greater than 30 years) were
recruited and a nasopharyngeal swab was taken to identify meningococcal carriers. Within
four weeks of the identification of a carrier, all members of the carrier’s household were invited
to participate in a longitudinal study [23]. Initial recruitment of a household to the longitudi-
nal study was based on the detection of a putative carrier of N. meningitidis employing conven-
tional microbiological methods, including serogrouping by agglutination. However,
confirmatory molecular assays conducted at the University of Oxford resulted in some isolates
being reclassified and this study is based on the results obtained following molecular character-
isation of species and genogroup. A blood sample and a pharyngeal swab which had touched
both the posterior pharynx and the tonsils were collected from all consenting members of the
participating household at the initial visit. Swabs were obtained subsequently twice a month
for two months and then monthly for a further four months up to a maximum of nine swabs
per person [21]. Compliance was high and 88% of individuals provided at least six swabs.
Transmission within households of genogroup A or C meningococci was detected only rarely
and therefore SBA assays were undertaken only for genogroups W, X and Y. Exploration of
the relationship between initial SBA titre and subsequent acquisition of carriage of genogroup
W or Y meningococci was undertaken in samples obtained from households in Ethiopia,
Ghana and Niger where transmission within households of meningococci belonging to these
genogroups was detected relatively frequently.
Laboratory methods
Isolation of N. meningitidis. The methods used to isolate and characterise N. meningitidis
have been described previously [21]. In brief, pharyngeal swabs were plated directly onto Mod-
ified Thayer Martin agar plates in the field and taken to the laboratory within six hours of col-
lection where they were incubated for 24–48 hours at 37˚C in 5% CO2. Suspected N.
meningitidis colonies identified on Thayer Martin plates were sub-cultured onto blood agar
plates and tested using an oxidase test, followed by a Gram stain. All oxidase positive, Gram-
negative diplococci underwent biochemical testing and those identified as N. meningitidis
were serogrouped by slide-agglutination using antisera for serogroups A, W, X and Y. To con-
firm the identity of Neisseria identified by culture techniques, aliquots of boiled suspensions of
all Gram-negative oxidase positive diplococci were sent to the University of Oxford for molec-
ular analysis as described previously. Amplification and sequencing of a fragment of the rplF
gene [24] was used to confirm the presence of, and differentiate between, Neisseria species
[25]. Confirmed N. meningitidis were characterised further using a multiplex real time PCR
assay detecting genogroups A, B, C, W, X and Y [26] and a sequencing assay detecting non-
capsulated meningococci [27].
Serum bactericidal antibody assay. SBAs were carried out as described previously [28].
Baby rabbit serum (Pel-Freeze) was used as the exogenous source of complement. Bactericidal
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antibody titres were expressed as the reciprocal of the final serum dilution giving 50% killing
after 60 minutes incubation. For computational purposes, titres <4 were assigned a value of 2.
Samples from Niger were tested against N. meningitidis serogroup W reference strain, W:
P1.18–1,3 (M01 240070). Samples from Ghana from households with at least one genogroup
W carrier were tested against two group W strains: a reference strain, W:P1.18–1,3 (M01
240070) and a local strain, W:P1.5,2. Samples from Ethiopia were tested against two test
strains: Y:P1.5,2 (M00242975) and X:P1.5–1,10–1.
Statistical methods
The terms used in the data analysis and their definitions are summarised in Table 1. Index car-
riers were defined as individuals within the household who were carriers of a meningococcus
of the SBA test genogroup at visit 0 (the initial cross-sectional survey) or visit 1. For individuals
with differing isolates at visits 0 and 1, determinate results were favoured over non-determi-
nate (ND) results. Only carriage events of the same genogroup as the index strain were consid-
ered. Index carriers were defined as individuals carrying a meningococcus of the SBA test
genogroup at visit 0 or 1. Determination of SBA titre in subjects who were a carrier on visit 1
and those who were not, allowed for an examination of the correlation between current car-
riage and SBA. Current carriers were stratified as those carrying a strain of the same gen-
ogroup and the same porA variable regions 1 and 2 as the SBA test strain, those carrying a
strain with the same genogroup but different porA, those carrying a strain with a different gen-
ogroup but the same porA, and those carrying a strain with a different genogroup and porA.
Secondary carriers were defined as non-index carriers who acquired a meningococcus of the
SBA test strain genogroup at least once during the study period. Non-carriers were defined as
non-index carriers who did not acquire a meningococcus belonging to the test strain gen-
ogroup at any time during the six-month follow-up period.
Logistic regression was used to identify risk factors for NmW acquisition, in particular sero-
logic status. Variables that attained univariate significance at P< 0.1 were added to a multivar-
iable model that included age group, serological status, and sex a priori. Those with a P value
of< .05 were retained. As a final check, dropped variables were re-entered into the model one
at a time; the variable was retained if P < .05.
Geometric mean titres (GMTs) and 95% confidence intervals were calculated using stan-
dard methods. Two different SBA reciprocal titres were evaluated as hypothetical correlates of
protection against acquisition of pharyngeal carriage of N. meningitidis. A reciprocal tire of 8
was selected based on the correlate of protection against invasive serogroup C meningococcal
disease [29], consistency with studies that have evaluated the immunogenicity of quadrivalent
meningococcal conjugate vaccines [30,31] and the titre used in other seroprevalence studies
[32]. A reciprocal titre 128 was selected as an alternative cut-off based on the distribution of
Table 1. Index and subsequent carriers by genogroup.
Genogroup Index carriers (Number) Subsequent carriers (Number)
A 0 0
W 45 28 [28]
X 1 0
Y 13 7 [7]
Non-groupable 4 1 [1]
Genogroup of the index case carrier and the number of additional carriers of N. meningitidis of the same
genogroup detected within these households in Ethiopia, Ghana or Niger during six months of follow-up.
https://doi.org/10.1371/journal.pone.0182575.t001
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titres found among participants in the present study. Because no carriage of any meningococci
with the porA P1.18,3 family (homologous with the group W reference strain) was detected in
the study, serological correlates of protection against acquisition of such strains could not be
evaluated.
Ethics
The purpose and methods of the study were explained to community leaders at community
meetings and through the media. Written, informed consent for obtaining a pharyngeal swab
and a blood sample was obtained from adults and for the children under their care. Written
informed assent was also obtained from participants aged 12 years or more. Oral assent was
obtained from younger children. Consent and assent forms were translated into the relevant
local language.
The study protocols, consent and assent forms were approved by the LSHTM Ethics Com-
mittee and by the ethics committees of each of the African partner institutions with the excep-
tion of Chad, which does not have a formal ethical committee, and where approval for the
activities of the consortium was granted by a committee set up to oversee MenAfriCar studies
by the Ministry of Health (S1 Table).
Results
Study participants
Nine hundred and ninety-three individuals from 147 households were recruited to the study,
747 (75%) of whom consented to have a blood sample taken. Two hundred and twenty-three
samples were obtained from individuals resident in households in which a carrier of gen-
ogroup W or Y was detected. One hundred and ninety were tested by SBA assay against one
strain of meningococcus of the corresponding genogroup and 33 against multiple strains. The
mean age of the individuals tested was 19.5 years, 51% were female. Fifty-one percent reported
receiving MenAfriVac or a “meningitis vaccine” during the time of a PsA-TT mass vaccination
campaign.
Index carriers and spread of N. meningitidis within household
The characteristics of the index carriers in the households recruited to the household study
and the subsequent transmission of meningococci of the same genogroup in these households
has been described in detail previously [23]. The genogroup distribution of the index carrier in
the households recruited to this serological study are summarised in Table 1. Because of the
infrequent occurrence of carriage of genogroup A N. meningitidis among the index cases and
the small number of genogroup X transmission events recorded, evaluation of serological cor-
relates of protection against acquisition of carriage with N. meningitidis has been restricted to
meningococci of genogroup W or Y.
Distribution of SBA titres and relation to acquisition of carriage
The overall distribution of SBA titres was bimodal for genogroups W, X and Y with a signifi-
cant proportion of “non-responders”–individuals with a titre of less than 8 –and an approxi-
mately normal distribution of ‘‘responders” with titres around a median of 512 (Fig 1). The
numbers of individuals with a titre of 8 or greater and those with a titre of 128 or greater
among index carriers, secondary carriers, and those who never carried are shown in (Table 2).
Individuals with a titre of genogroup W SBA of 128 or greater of were found significantly
Correlates of protection against meningococcal carriage in the African meningitis belt
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more frequently among current carriers than among individuals in the other two groups
(p< 0.01 and p< 0.01 respectively).
Geometric mean titres were significantly higher among index carriers for the group W ref-
erence strain (360 [95% CI 190–660]) compared with the GMT in the other two groups (21
[95% CI 12–36] and 14 [95% CI 12–16] respectively) (Fig 2). There was no difference in GMT
against the Ghana W strain and the group W reference strain between index carriers and sec-
ondary carriers, although both were significantly higher than non-carriers. The distribution of
titres at the time of recruitment between individuals who were not carrying at the time of
recruitment but who became a carrier of a meningococcus of the same genogroup as index
case and those who did not is shown in Fig 3. The patterns are very similar with no suggestion
that titres on enrolment were higher in individuals who did not become a carrier than in those
who did.
Fig 1. SBA titre distribution. Overall distribution of SBA titres in all household members tested against the reference
strains of N. meningitidis genogroups W, X and Y and against a local Ghanaian genogroup W strain.
https://doi.org/10.1371/journal.pone.0182575.g001
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Risk factors for genogroup W acquisition
Risk factors for acquisition of a genogroup W strain at the individual level are shown in
Table 3. Age, meningococcal vaccination status and crowding were associated with higher
odds of acquisition of carriage in a univariate analysis but only age remained a significant risk
factor in a multivariate logistic analysis. Having a group W SBA titre of less than 8 was not a
significant risk factor for acquisition, suggesting that SBA titres greater than or equal to 8 can-
not be considered a correlate of protection against carriage acquisition. The same results were
achieved with a higher cut-off threshold of 128.
Influence of the test strain on SBA geometric mean titre
SBA GMTs to the serogroup W reference strain (W:P1.18–1,3) were significantly higher
among carriers of genogroup W strains than among carriers of heterologous strains (320 [95%
CI 140–720] versus 7.3 [95% CI 4.0–13]). This was not true for serogroup Y SBA GMTs, and
could not be evaluated for serogroup X or the Ghanaian serogroup W strain. Titres against the
local Ghanaian group W strain and the group W reference strain were highly correlated (Pear-
son’s rho of 0.95, n = 42). For the 12 individuals carrying the Ghana strain at the time of
recruitment, titres against this strain were tightly correlated with titres against the reference W
strain (Pearson’s rho = 0.99, p< 0.001)
Discussion
We have investigated the role of serum bactericidal antibodies in acquisition of meningococcal
carriage by following households with known exposure from an index carrier. Surprisingly, we
found no evidence of an association between SBA titre and protection against acquisition of
group W or Y carriage in subjects exposed to a meningococcus of the homologous genogroup.
Table 2. Antibody titres by exposure and outcome.
Serum bactericidal antibody titre
<8
No. [%]
8
No. [%]
 128
No. [%]
Genogroup W
Carrier on recruitment 9 [20] 36 [80] 35 [78]
Not a carrier on recruitment 209 [64] 117 [36] 107 [33]
Subsequent carrier 37 [62] 23 [38] 21 [35]
In households with a carrier 18 [64] 10 [36] 9 [32]
Non-carrier 172 [65] 94 [35] 86 [32]
In households with a carrier 67 [59] 46 [41] 43 [38]
Genogroup Y
Carrier on recruitment 1 [9] 10 [91] 9 [82]
Not a carrier on recruitment 39 [30] 92 [70] 91 [69]
Subsequent carrier 1 [14] 6 [86] 6 [86]
In households with a carrier 1 [14] 6 [86] 6 [86]
Non-carrier 38 [31] 86 [69] 85 [69]
In households with a carrier 6 [32] 13 [68] 12 [63]
The number and percentage of individuals with an initial SBA of 8 or greater, or with a titre of 128 or greater
in initial carriers, subjects who subsequently became a carrier of N. meningitidis of the same genogroup as
the index case and those who did not become a carrier of N. meningitidis of this genogroup during the six
months of follow-up.
https://doi.org/10.1371/journal.pone.0182575.t002
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This was the case even after correction for other variables such as age, sex, and place of resi-
dence. Serum bactericidal antibodies, acquired as a result of natural exposure or vaccination,
are associated with protection against invasive meningococcal disease [6–9] but we are not
aware of any previous study which has investigated the association of SBA with protection
against acquisition of meningococcal carriage. Previous studies of subjects vaccinated with
Hib or pneumococcal conjugate vaccines have suggested that higher titres of IgG antibody are
required to protect against pharyngeal carriage than against invasive disease [17–19], as might
be expected if protection is dependent upon diffusion of antibodies from the blood to the
mucosa.
There are a number of possible explanations for our finding of a lack of correlation between
SBA titres and risk of acquisition of pharyngeal carriage with N. meningitidis. It is possible that
Fig 2. Geometric mean by exposure and outcome. Geometric mean SBA titres and 95% CI found in current carriers of
N. meningitidis genogroup W or Y and in household members exposed to a carrier who became a carrier of N. meningitidis
of the same genogroup as the index case and among those who did not.
https://doi.org/10.1371/journal.pone.0182575.g002
Correlates of protection against meningococcal carriage in the African meningitis belt
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SBAs were performed using a strain which was not able to detect protective antibodies against
the strains circulating in the study households. However, we found a very close correlation
between responses to the W reference strain compared to the locally isolated genogroup W
strain. In addition, SBA titres of individuals who were a carrier on entry into the study had a
significantly higher SBA titre than individuals who were not a carrier suggesting that the assay
was detecting responses to the local strain making strain variation an unlikely explanation for
our findings. Secondly, it is possible that natural exposure to infection does not induce SBA at
a high enough titre to provide protection whilst vaccination may do so. Evidence to support
this hypothesis is provided by the fact that the GMT of SBA to N. meningitidis genogroup W
or Y found in individuals in this study (< 1000) was lower than the GMT found in adolescents
or young adults one month after vaccination with a quadrivalent meningococcal conjugate
Fig 3. Reciprocal titre by exposure and outcome. Reciprocal plots of SBA titre found in individuals exposed to a carrier
of N. meningitidis who became a carrier of a meningococcus belonging to the same genogroup as the index carrier during
six months of follow-up and those who did not. Sera tested against a genogroup W reference strain, genogroup W local
strain, genogroup Y reference strain.
https://doi.org/10.1371/journal.pone.0182575.g003
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vaccine employing a SBA that used baby rabbit serum as a source of complement (8390 [95%
CI 7777, 9051] for genogroup W and 13865 [95% CI 12968, 114824] for genogroup Y respec-
tively [33]. Similarly, the GMT induced by the serogroup A conjugate vaccine MenAfriVac
was 4700 (95% CI 4300, 5100) one month after vaccination in those aged 2 to 29 years and
6200 (95% CI 4900, 7900) in those aged 1 to 2 years [9]. However, some individuals in this
study with titres of 4096 and higher, within the range of responses induced by these conjugate
vaccines, became a carrier of a meningococcus of the same genogroup. Thirdly, it is possible
that the affinity or isotype of antibodies induced by natural infection is different from that
induced by conjugate vaccination and less able to provide protection against acquisition of car-
riage. Fourthly, it is possible that in the harsh environment of the African meningitis belt up-
regulation of CECAM expression facilitates binding of meningococci to the epithelium even in
the presence of moderately high concentrations of anti-capsular antibody. In other words,
meningococci may carry the gene for a particular capsule but may or may not express it under
different circumstances, and this means that an immune response targeting primarily the cap-
sular antigen may not protect against future acquisition. Finally, it is possible that the primary
means of naturally acquired protection against carriage of the meningococcus is not mediated
though serum bactericidal antibody but by locally induced mucosal immune mechanism or by
a cell mediated immune response as has been suggested to be the case for S. pneumoniae [34],
a possibility that warrants further investigation.
This study has a number of weaknesses. Firstly, it was not possible to test all sera collected
during the household studies against all genogroups and some selection of samples was
required. This was done on the basis of selecting samples which would be able to provide the
strongest evidence of whether or not SBAs were protective against acquisition of carriage. Sub-
jects were selected on the basis of known exposure to a carrier and from households where
Table 3. Factors influencing odds of carriage acquisition.
Factor Subjects (Secondary carriers) Crude OR (95% CI) Adjusted OR (95% CI)
Group W SBA titre
<8 165 (29) 1.0 1.0
8 103 (21) 1.20 (0.64–2.24) 1.13 (0.59–2.15)
Age (years)
<5 55 (13) 2.61 (0.98–7.47) 2.60 (0.98–7.46)
5–14 70 (21) 3.61 (1.48–9.82) 3.50 (1.42–9.59)
15–29 66 (7) 1.0 1.0
30 77 (9) 1.12 (0.39–3.30) 1.12 (0.39–3.31)
Sex
Female 143 (24) 1.0 1.0
Male 125 (26) 1.30 (0.70–2.42) 1.14 (0.60–2.17)
Household exposure
No group W index carrier 141 (26) 1.0 . . .
Group W index carrier 127 (24) 1.03 (0.55–1.91) . . .
Vaccination status
Not vaccinated 84 (10) 1.0 . . .
Any history of vaccination 184 (40) 2.06 (1.01–4.56) . . .
Crowding
<4 people per bedroom 92 (10) 1.0 . . .
4 people per bedroom 176 (40) 2.41 (1.19–5.34) . . .
Univariable and multivariable logistic regression analysis of factors associated with genogroup W N. meningitidis acquisition.
https://doi.org/10.1371/journal.pone.0182575.t003
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transmission events with genogroup W or Y meningococci dominated. Secondly, we have
assumed that subjects who became carriers and those did not were equally exposed to the
index carrier and this may not have been the case, although the crowded nature of most of the
study households make this likely. Age is likely to have been an important factor influencing
contact with the carrier and the lack of association between SBA and protection against acqui-
sition of carriage persisted even after an age correction had been made. Age will also have
influenced likely number of previous infections. All study sites fall within the meningitis belt,
and as such experience frequent epidemics. In particular, outbreaks (greater than 60 suspected
cases per 100,000 population annually) were documented in 2006 in both sites in Niger and in
2010–2012 in both sites in Ghana. [35]
This study has shown that the SBA titres induced by natural exposure to infection with N.
meningitidis of genogroup W or Y are not associated with protection against acquisition of car-
riage of meningococci of the same genogroup, as might have been expected. A more detailed
study which provided more information on patterns of contact within a household and which
studied immunological correlates in addition to SBA could be rewarding.
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